Formulation of piperine solid lipid nanoparticles (SLN) for treatment of rheumatoid arthritis.
The purpose of this work was to formulate piperine solid lipid nanoparticle (SLN) dispersion to exploit its efficacy orally and topically. Piperine SLN were prepared by melt emulsification method and formula was optimized by the application of 32factorial design. The nanoparticulate dispersion was evaluated for particle size, entrapment efficiency and zeta potential (ZP). Optimized batch (128.80 nm average size, 78.71% entrapment efficiency and -23.34 mV zeta potential) was characterized for differential scanning calorimetry (DSC), X-ray diffraction which revealed amorphous nature of piperine in SLN. The prepared SLN were administered orally and topically to CFA-induced arthritic rats. Ex vivo study using Franz diffusion cell indicate that piperine from SLN gel formulation accumulates in the skin. Pharmacodynamic study result indicates both the topical and oral piperine evoked a significant response compared to orally administered chloroquine suspension. The results of ELISA show significant reduction in TNFα in treated rat which might be the reason behind the DMARD action of piperine SLN.
a Department of Pharmaceutics , AISSMS College of Pharmacy , Pune , India.
Mangesh R
MR
Bhalekar
a Department of Pharmaceutics , AISSMS College of Pharmacy , Pune , India.
Ashwini R
AR
Madgulkar
a Department of Pharmaceutics , AISSMS College of Pharmacy , Pune , India.
Puja S
PS
Desale
a Department of Pharmaceutics , AISSMS College of Pharmacy , Pune , India.
Gyce
G
Marium
D000470:Alkaloids / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D052117:Benzodioxoles / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D004339:Drug Compounding; D005079:Excipients; D005620:Freund's Adjuvant; D066298:In Vitro Techniques; D008055:Lipids / Q000737:chemistry; D008297:Male; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D010880:Piperidines / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D053284:Polyunsaturated Alkamides / Q000008:administration & dosage* / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013501:Surface-Active Agents
D000470:Alkaloids; D000894:Anti-Inflammatory Agents, Non-Steroidal; D052117:Benzodioxoles; D005079:Excipients; D008055:Lipids; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D013501:Surface-Active Agents; D005620:Freund's Adjuvant; C008922:piperine
CIA; ELISA; Rheumatoid arthritis; SLN (solid lipid nanoparticles); TNFα; optimization; piperine